CLINICAL TRIALS

Can This ASX Junior Surge Through the Pain Barrier?

Next Investors Archived Mar 02, 2020

Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.

Antisense appoints experienced biotech executive

Finfeed Archived Feb 28, 2020

Antisense Therapeutics Limited (ASX:ANP) has appointed Gil Price M.D. as Consultant Medical Director. Dr. Price is a clinical physician trained in internal medicine with a long-standing focus in drug development, adverse drug reactions, drug utilization and regulation.

PharmAust Expands Site Recruitment for Phase II Pet Dog Cancer Trial

Finfeed Archived Dec 11, 2019

PharmAust Ltd (ASX:PAA), a clinical-stage oncology company that’s developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.

Ten ‘TechKnows’ to test drive

Finfeed Archived Oct 23, 2019

The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies.

Imugene to demonstrate the benefits of combination tumor treatment

Finfeed Archived Oct 21, 2019

Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.

Rat's Rant: What's hot, what's not and ... The Canberra Raiders

Finfeed Archived Oct 01, 2019

Change Financial Limited (ASX:CCA) closed up 332% to finish at 54c on $11.2 million stock traded on the back of the successful completion of the build of its innovative payments and card issuing platform marking a key milestone for the company.

A healthy six pack in a hot sector: Part 2

Finfeed Archived Sep 11, 2019

The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.

Imagion MRI applications as a new source of revenue

Finfeed Archived Sep 09, 2019

Imagion Biosystems (ASX:IBX) advised the market of early-stage evidence that the technology could have applications in improving magnetic resonance imaging (MRIs).

Immuron shares soar more than 20%

Finfeed Archived Sep 04, 2019

Immuron’s (ASX:IMC) share price has surged on the back of extremely promising clinical results.

Immuron delivers another year of strong sales growth

Finfeed Archived Sep 02, 2019

Travelan is Immuron’s (ASX:IMC) over-the-counter gastrointestinal and digestive health supplement, and global sales increased by 29.5% year-on-year in fiscal 2019 to $2.39 million.

Australia’s top biotechs descend on Queenstown for the 2019 Bioshares Summit

Finfeed Archived Jul 25, 2019

Queenstown, the New Zealand extreme sport mecca, hosts the annual Bioshares Biotech Summit, gathering together some of the best long-standing and emerging biotech companies in the country to talk all things trials, tribulations and potential cures for cancer.

Trial success may open up options for BPH

Finfeed Archived Jul 03, 2019

BPH Energy Ltd (ASX:BPH) has provided a promising update relating to further trials for the BARM System of investee Cortical Dynamics Ltd.

Immuron’s shares rise on the back of Travelan® results

Finfeed Archived Jun 12, 2019

Immuron Ltd (ASX:IMC; NASDQ:IMRN), has provided an extremely promising update on the company’s cooperative research and development agreements with the US Department of Defence, no doubt contributing to its strong share price performance on the back of this news.

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

Next Investors Archived Apr 08, 2019

Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.

Imugene releases encouraging HER-Vaxx trial results

Finfeed Archived Apr 02, 2019

Imugene Limited (ASX:IMU), a leading clinical stage immuno-oncology company, has today released new data on the Phase lb study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia.

Clinical Trials